The development of human serum albumin-based drugs and relevant fusion proteins for cancer therapy

Tao, Hongyu; Wang, Ruiqi; Sheng, Weijin; Zhen, Yong‐Su

doi:10.1016/j.ijbiomac.2021.07.080

Cited by 68 publications

(29 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another approach to promote interaction with albumin is to alter targeted delivery [7,[95][96][97][98]. Several technologies with albumin are possible to encapsulate the drugs in the nanoparticles.…”

Section: Noncovalent Strategymentioning

confidence: 99%

Serum Albumin for Magnetic Nanoparticles Coating

Chubarov

2022

Magnetochemistry

View full text Add to dashboard Cite

Magnetic nanoparticles (MNPs) have great potential in biochemistry and medical science. In particular, iron oxide nanoparticles have demonstrated a promising effect in various biomedical applications due to their high magnetic properties, large surface area, stability, and easy functionalization. However, colloidal stability, biocompatibility, and potential toxicity of MNPs in physiological environments are crucial for their in vivo application. In this context, many research articles focused on the possible procedures for MNPs coating to improve their physic-chemical and biological properties. This review highlights one viable fabrication strategy of biocompatible iron oxide nanoparticles using human serum albumin (HSA). HSA is mainly a transport protein with many functions in various fundamental processes. As it is one of the most abundant plasma proteins, not a single drug in the blood passes without its strength test. It influences the stability, pharmacokinetics, and biodistribution of different drug-delivery systems by binding or forming its protein corona on the surface. The development of albumin-based drug carriers is gaining increasing importance in the targeted delivery of cancer therapy. Considering this, HSA is a highly potential candidate for nanoparticles coating and theranostics area and can provide biocompatibility, prolonged blood circulation, and possibly resolve the drug-resistance cancer problem.

show abstract

Section: Noncovalent Strategymentioning

confidence: 99%

Serum Albumin for Magnetic Nanoparticles Coating

Chubarov

2022

Magnetochemistry

View full text Add to dashboard Cite

show abstract

“…Human serum albumin (HSA) is the most abundant blood plasma protein, with an average half-life of three weeks and a hydrodynamic radius of around 7 nm, that has shown great potential for drug delivery thanks to its physiological role as a carrier protein for endogenous and exogenous substances [ 8 , 9 ]. HSA has been employed to form nanoparticles (NPs) with different anticancer drugs, enhancing their delivery at the tumor tissues thanks to the EPR effect and to the over-expression of specific HSA-binding proteins, such as gp60 and SPARC (secreted protein acidic and rich in cysteine) [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

“…HSA has been employed to form nanoparticles (NPs) with different anticancer drugs, enhancing their delivery at the tumor tissues thanks to the EPR effect and to the over-expression of specific HSA-binding proteins, such as gp60 and SPARC (secreted protein acidic and rich in cysteine) [ 10 ]. These proteins play an essential role in the selective internalization and accumulation of HSA-based NPs and HSA-bound drugs into the tumor interstitium [ 9 , 11 ], making HSA an attractive, safe and inexpensive molecule for the preparation of nano-structured carriers for drugs to enhance their circulation half-life and targeting.…”

Section: Introductionmentioning

confidence: 99%

HSA-Binding Prodrugs-Based Nanoparticles Endowed with Chemo and Photo-Toxicity against Breast Cancer

Rapozzi

Moret

Menilli

et al. 2022

Cancers

View full text Add to dashboard Cite

Exploiting the tumor environment features (EPR effect, elevated glutathione, reactive oxygen species levels) might allow attaining a selective and responsive carrier capable of improving the therapeutic outcome. To this purpose, the in situ covalent binding of drugs and nanoparticles to circulating human serum albumin (HSA) might represent a pioneering approach to achieve an effective strategy. This study describes the synthesis, in vitro and in vivo evaluation of bioresponsive HSA-binding nanoparticles (MAL-PTX2S@Pba), co-delivering two different paclitaxel (PTX) prodrugs and the photosensitizer pheophorbide a (Pba), for the combined photo- and chemo-treatment of breast cancer. Stable and reproducible MAL-PTX2S@Pba nanoparticles with an average diameter of 82 nm and a PTX/Pba molar ratio of 2.5 were obtained by nanoprecipitation. The in vitro 2D combination experiments revealed that MAL-PTX2S@Pba treatment induces a strong inhibition of cell viability of MDA-MB-231, MCF7 and 4T1 cell lines, whereas 3D experiments displayed different trends: while MAL-PTX2S@Pba effectiveness was confirmed against MDA-MB-231 spheroids, the 4T1 model exhibited marked resistance. Lastly, despite using a low PTX-PDT regimen (e.g., 8.16 mg/Kg PTX and 2.34 mg/Kg Pba), our formulation showed to foster primary tumor reduction and curb lung metastases growth in 4T1 tumor-bearing mice, thus setting the basis for further preclinical validations.

show abstract

“…[4][5][6][7][8][9] Among others, the dynamic hydrazone bond has been demonstrated as an efficient tool to conjugate drugs to produce various polymeric and macromolecular prodrugs, [9][10][11][12] which release active agents via acid-responsive hydrolysis in the tumour microenvironment. In the category of macromolecular conjugates, albumin-binding prodrugs have been exploited ex vivo and in vivo due to their accumulation in solid tumours, low toxicity or immunogenicity and high abundance in blood, [13][14][15][16][17] and there are already albumin-binding prodrugs being studied in clinical trials. 13,18 In the in vivo albumin-conjugation category, aldoxorubicin (AlDox), formerly known as , is a promising antitumour prodrug of doxorubicin (Dox) that has been undergoing clinical trials.…”

Section: Introductionmentioning

confidence: 99%